{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.4019",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2020-12-17T01:00:39.000-05:00",
    "profile" : ["http://hl7.org/fhir/StructureDefinition/shareablevalueset",
    "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
    "valueString" : "Clinical Architecture"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
    "valueDate" : "2023-06-21"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
    "valueDate" : "2020-12-17"
  }],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4019",
  "identifier" : [{
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4019"
  }],
  "version" : "20201217",
  "name" : "COVID19ICD10PCSValueSetForAdministrationOfTocilizumab",
  "title" : "COVID19 ICD10PCS Value Set for Administration of Tocilizumab",
  "status" : "active",
  "experimental" : false,
  "date" : "2023-06-21T18:16:37-04:00",
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [{
    "extension" : [{
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
      "valueString" : "UNKNOWN"
    }]
  }],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of tocilizumab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of tocilizumab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other interleukin-6 antagonists (e.g., sarilumab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "compose" : {
    "include" : [{
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "concept" : [{
        "code" : "XW033H5",
        "display" : "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"
      },
      {
        "code" : "XW043H5",
        "display" : "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"
      }]
    }]
  },
  "expansion" : {
    "identifier" : "urn:uuid:c3db86fd-45ed-49c9-b584-61ae19179f95",
    "timestamp" : "2023-09-26T09:42:59-04:00",
    "total" : 2,
    "offset" : 0,
    "parameter" : [{
      "name" : "count",
      "valueInteger" : 1000
    },
    {
      "name" : "offset",
      "valueInteger" : 0
    }],
    "contains" : [{
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "version" : "2024",
      "code" : "XW033H5",
      "display" : "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"
    },
    {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "version" : "2024",
      "code" : "XW043H5",
      "display" : "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"
    }]
  }
}